1991 - Fellow of John Simon Guggenheim Memorial Foundation
His primary areas of study are Molecular biology, Antibody, Cancer research, Monoclonal antibody and Antigen. Mark I. Greene has included themes like Receptor, Cell surface receptor, Idiotype, Epitope and Gene product in his Molecular biology study. His studies in Antibody integrate themes in fields like Oncogene, 3T3 cells, In vivo and Immunotherapy.
His research in Cancer research intersects with topics in Cancer, Protein tyrosine phosphatase, Transcription factor, Tumor suppressor gene and FOXP3. His Monoclonal antibody research is multidisciplinary, incorporating perspectives in Cell culture, Biochemistry, Peptide and Tumor antigen. His Antigen study necessitates a more in-depth grasp of Immunology.
Mark I. Greene mainly focuses on Molecular biology, Immunology, Cell biology, Antigen and Antibody. The study incorporates disciplines such as Cell culture, Receptor, Spleen, Idiotype and Epitope in addition to Molecular biology. He combines subjects such as Suppressor, Cancer research and In vivo with his study of Immunology.
His Cell biology research focuses on FOXP3 and how it connects with Transcription factor. The Antigen study combines topics in areas such as Cell and Tumor antigen. His works in Monoclonal antibody and Monoclonal are all subjects of inquiry into Antibody.
Mark I. Greene mostly deals with Cancer research, Cell biology, FOXP3, Immunology and Immune system. His study in Cancer research is interdisciplinary in nature, drawing from both Cancer cell, Cancer, Targeted therapy, ErbB and Monoclonal antibody. His studies deal with areas such as Molecular biology, Tyrosine kinase and Ifn gamma as well as ErbB.
The various areas that Mark I. Greene examines in his Molecular biology study include Platelet factor 4 and Cell culture. His research in Monoclonal antibody intersects with topics in Prostate cancer and Antigen. In his research, Antigen binding is intimately related to Biochemistry, which falls under the overarching field of Cell biology.
Mark I. Greene mainly investigates Cancer research, Cell biology, FOXP3, Transcription factor and Immunology. His studies in Cancer research integrate themes in fields like Cancer cell, Cell cycle, Targeted therapy and Metastasis. His Transcription factor research includes elements of Survivin, Immune system, Function, Regulator and Histone.
His Immunology study combines topics from a wide range of disciplines, such as Breast carcinoma and Breast disease. His work is dedicated to discovering how Immunotherapy, Acquired immune system are connected with Antibody and other disciplines. Mark I. Greene usually deals with Antibody and limits it to topics linked to Glycan and Prostate, Prostate cancer, Antigen and Monoclonal antibody.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen.
Alan L. Schechter;David F. Stern;Lalitha Vaidyanathan;Stuart J. Decker.
Deacetylase inhibition promotes the generation and function of regulatory T cells
Ran Tao;Edwin F de Zoeten;Engin Özkaynak;Chunxia Chen.
Nature Medicine (2007)
Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer
Yukiko Tone;Keiji Furuuchi;Yoshitsugu Kojima;Mark L Tykocinski.
Nature Immunology (2008)
ErbB receptors: from oncogenes to targeted cancer therapies
Hongtao Zhang;Alan Berezov;Qiang Wang;Geng Zhang.
Journal of Clinical Investigation (2007)
p185neu Expression in Human Lung Adenocarcinomas Predicts Shortened Survival
Jeffrey A. Kern;David A. Schwartz;Joanne E. Nordberg;David B. Weiner.
Cancer Research (1990)
Bound water molecules and conformational stabilization help mediate an antigen-antibody association.
T N Bhat;G A Bentley;G Boulot;M I Greene.
Proceedings of the National Academy of Sciences of the United States of America (1994)
A point mutation in the neu oncogene mimics ligand induction of receptor aggregation
David B. Weiner;Jing Liu;Jeffrey A. Cohen;William V. Williams.
Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies.
Jeffrey A. Drebin;Victoria C. Link;Victoria C. Link;David F. Stern;Robert A. Weinberg.
Regulation of the Immune Response to Tumor Antigens I. Immunosuppressor Cells in Tumor-Bearing Hosts
Shigeyoshi Fujimoto;Mark I. Greene;Alec H. Sehon.
Journal of Immunology (1976)
The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
Sae Gwang Park;Zhujun Jiang;Eric D. Mortenson;Liufu Deng.
Cancer Cell (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: